![]()
|
Report Date : |
22.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
ANTIBIOTIC SAZI IRAN COMPANY |
|
|
|
|
Registered Office : |
No.3, Bistoon St,
Jahad (Fatemi) Sq Tehran 14316 63113 |
|
|
|
|
Country : |
Iran |
|
|
|
|
Date of Incorporation : |
1995 |
|
|
|
|
Com. Reg. No.: |
119201 |
|
|
|
|
Legal Form : |
Privet Joint
Stock Company |
|
|
|
|
Line of Business : |
Manufacture of Raw Material
Production, Mainly Oral Antibiotics from Penicillin |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Company Name: Antibiotic Sazi
Iran Company
Also Trade Name: ASICO
Headquarter
Address: No.3, Bistoon St, Jahad (Fatemi) Sq
Tehran 14316 63113
Iran
Tel: +98 21 88962978
+98
21 88962979
Fax: +98 21 88962478
Website: www.antibiotic-ir.com
E-mail: asico@antibiotic-ir.com
Current Legal Form: Privet Joint Stock Company
Registration Address: No.3, Bistoon St, Jahad
(Fatemi) Sq
Tehran
Iran
Registration Number: 119201
Registration Date: 1995
Year Established: 1995
Registration Town: Tehran
Currency: Iranian Rials
Nominal capital: 80,000,000,000
|
Number of Shares: 8,000,000 |
Type of Shares: None Selected |
|
Issued Shares: - |
Value per share: IRI 10,000.00 |
|
Shareholder Names/ Address |
% of Voting/Non-Voting Capital |
|
Farabi Pharmaceutical Co Tehran Iran |
%38 |
|
Social Security Organization Tehran Iran |
%32 |
|
Taamin
Investment Company Tehran Iran |
%10 |
|
Others Iran |
%20 |
Name: Mr. Seyed Mehdi Mousavi
Position within the company: Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Ali Aminlou
Position within the company: Vice Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Kourosh Soleymani
Meygouni
Position within the company: Managing Director
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi
Name: Mr. Mohamad Tahsiri
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi
Manufacture of Raw material
production, mainly oral antibiotics from penicillin
Local Reporters consider the investigated company to be
Medium their field of concern.
Company Employs: 250
Operates from: Owned Offices, Warehouses,
Factory
Location: Central Business Area, Main Road
Branch:
Antibiotic Sazi Iran Factory
5th Km, Khazar Abad Road
Sari
Iran
Branch is owned
Imports:
Import%: 20% Raw Material, 15%
Finished Good
Import from: Germany, Swiss, Japan,
India
Import terms: letters of credit
Additional: alance of 65%
purchased via local market
Exports: Finished Goods
Export%: 20%
Export from: Persian Gulf Countries,
CIS
Export terms: letters of credit
Territory: 80% Nationality, 20 % Internationally
Type of Customer: General Public, Local Authorities
Terms of sales: Cash, letters of credit
Vehicles: Total number of vehicles: 40
Subject Dose not have related company
Bank Melli
Tehran
Iran
Bank Tejarat
Tehran
Iran
Source: Mr. Ahmad Mohamadi (Secretary)
Currency: Iranian Rials -
000,000
|
Months |
Date |
Sales |
|
12 |
29/03/2007 |
91000 |
|
12 |
29/03/2006 |
74000 |
|
12 |
29/03/2005 |
62000 |
Subject's payments reported to be: NO COMPLAINTS
Name/Title: Mr. Ahmad Mohamadi (Secretary)
In the interview conducted with Mr. Ahmad Mohamadi (Secretary), he Declined full financial
information and bank account numbers citing
the grounds of Company confidentiality.
Local Reputation: The company being investigated is considered by local reporters to be a
Medium Trade Risk.
General Conclusion:
Local informants consider granting of credit to be a fair trade risk.
Owner/Shareholders Comments:
Some of owners involved in the running of
the business
Age of Business: Old
Business
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)